AGENT FOR STROKE THERAPY

International application PCT/RU2019/050138, priority 05.09.2018

Patent applications for inventions

• Russia No.2018131831 stated 05.09.2018

Afusionprotein with prolonged neuroprotective activity based on IGF-1 has been developed, as wellasa method for treating stroke, including intranasal administration of such afusionprotein to the patient.The introduction of afusionprotein according to the invention is preferably carried out as soon aspossible after the onset of a stroke.

It is also proposed to use the developed protein for the treatment or prevention of other diseases orconditions for the treatment of which neuroprotective activity or other activity inherent in IGF-1 isnecessary or favorable.

Assessment of the significance of these developments